Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Fangteng Liu & Hengyu Wu. (2021) Identification of Prognostic Biomarkers and Molecular Targets Among JAK Family in Breast Cancer. Journal of Inflammation Research 14, pages 97-114.
Read now
Read now
Yuanjue Sun, Liguo Liu, Yaling Wang, Aina He, Haiyan Hu, Jianjun Zhang, Mingyong Han & Yujing Huang. (2019) Curcumin inhibits the proliferation and invasion of MG-63 cells through inactivation of the p-JAK2/p-STAT3 pathway. OncoTargets and Therapy 12, pages 2011-2021.
Read now
Read now
Howard A. Burris$suffix/text()$suffix/text(). (2018) Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Expert Review of Anticancer Therapy 18:3, pages 201-213.
Read now
Read now
Christina Y. Yim, Emmanuel Bikorimana, Ema Khan, Joshua M. Warzecha, Leah Shin, Jennifer Rodriguez, Ethan Dmitrovsky, Sarah J. Freemantle & Michael J. Spinella. (2017) G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer. Cell Cycle 16:21, pages 2146-2155.
Read now
Read now
Moataz Ehab & Mohamad Elbaz. (2016) Profile of palbociclib in the treatment of metastatic breast cancer. Breast Cancer: Targets and Therapy 8, pages 83-91.
Read now
Read now
Ciara C. O’Sullivan. (2016) CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update. Expert Opinion on Pharmacotherapy 17:12, pages 1657-1667.
Read now
Read now
María José de Miguel-Luken, Manuel Chaves-Conde & Amancio Carnero. (2016) A genetic view of laryngeal cancer heterogeneity. Cell Cycle 15:9, pages 1202-1212.
Read now
Read now
Eric Haines, Sabrina Schlienger & Audrey Claing. (2015) The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors. Cancer Biology & Therapy 16:10, pages 1535-1547.
Read now
Read now
Articles from other publishers (12)
Madeleine Hetterich & Olaf Ortmann. (2023) Endokrin kombinierte Therapie des metastasierten Mammakarzinoms – Lebensqualität und Lebensverlängerung durch zielgerichtete Tumortherapie. TumorDiagnostik & Therapie 44:02, pages 115-124.
Crossref
Crossref
Kunrui Zhu, Yanqi Wu, Ping He, Yu Fan, Xiaorong Zhong, Hong Zheng & Ting Luo. (2022) PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer. Cells 11:16, pages 2508.
Crossref
Crossref
Madeleine Hetterich & Olaf Ortmann. (2021) Lebensqualität und Lebensverlängerung durch endokrin kombinierte Tumortherapie. Frauenheilkunde up2date 15:06, pages 497-513.
Crossref
Crossref
Giovanna Garufi, Luisa Carbognin, Armando Orlandi, Antonella Palazzo, Giampaolo Tortora & Emilio Bria. (2021) The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature. Frontiers in Oncology 11.
Crossref
Crossref
Natália Lourenço de Freitas, Maria Gabriela Deberaldini, Diana Gomes, Aline Renata Pavan, Ângela Sousa, Jean Leandro Dos Santos & Christiane P. Soares. (2021) Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Jingwei Yao, Kun Deng, Jialu Huang, Ruimin Zeng & Jianhong Zuo. (2020) Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer. Frontiers in Pharmacology 11.
Crossref
Crossref
Marianna Sirico, Ottavia Bernocchi, Navid Sobhani, Fabiola Giudici, Silvia P. Corona, Claudio Vernieri, Federico Nichetti, Maria Rosa Cappelletti, Manuela Milani, Carla Strina, Valeria Cervoni, Giuseppina Barbieri, Nicoletta Ziglioli, Martina Dester, Giulia Valeria Bianchi, Filippo De Braud & Daniele Generali. (2020) Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancers 12:11, pages 3314.
Crossref
Crossref
Yang Song, Mei-Yue Tang, Wei Chen, Zhe Wang & Si-Liang Wang. (2020) High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Disease Markers 2020, pages 1-8.
Crossref
Crossref
Giulia Occhipinti, Emanuela Romagnoli, Matteo Santoni, Alessia Cimadamore, Giulia Sorgentoni, Monia Cecati, Matteo Giulietti, Nicola Battelli, Alessandro Maccioni, Nadia Storti, Liang Cheng, Giovanni Principato, Rodolfo Montironi & Francesco Piva. (2020) Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications. Frontiers in Genetics 11.
Crossref
Crossref
Tzelepi C. Vasiliki, Gogadis T. Aristeidis, Adamidis K. Christos & Eleni T. Timotheadou. (2019) The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer. Forum of Clinical Oncology 10:2, pages 2-14.
Crossref
Crossref
Nenad Markovic, Ana Lukovic, Nebojsa Arsenijevic, Srdjan Ninkovic & Biljana Ljujic. (2018) The Role of Tumor Microenvironment and Impact of Cancer Stem Cells on Breast Cancer Progression and Growth. Serbian Journal of Experimental and Clinical Research 0:0.
Crossref
Crossref
Puja Khanna, Joan Shuying Lee, Amornpun Sereemaspun, Haeryun Lee & Gyeong Hun Baeg. (2018) GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling. Scientific Reports 8:1.
Crossref
Crossref